Search

Daniel M. Sullivan

Director (ID: 12309, Phone: (571)272-0900 , Office: P/1600 )

Most Active Art Unit
1636
Art Unit(s)
1600, 1611, 1621, 1636
Total Applications
646
Issued Applications
156
Pending Applications
192
Abandoned Applications
334

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18649524 [patent_doc_number] => 20230295340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => MUC1* ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/062377 [patent_app_country] => US [patent_app_date] => 2022-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062377 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/062377
MUC1* ANTIBODIES Dec 5, 2022 Abandoned
Array ( [id] => 18376017 [patent_doc_number] => 20230151099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/993567 [patent_app_country] => US [patent_app_date] => 2022-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17993567 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/993567
COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS Nov 22, 2022 Pending
Array ( [id] => 18612385 [patent_doc_number] => 20230279117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => ANTI-PD-L1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS [patent_app_type] => utility [patent_app_number] => 18/050441 [patent_app_country] => US [patent_app_date] => 2022-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050441 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/050441
ANTI-PD-L1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS Oct 26, 2022 Abandoned
Array ( [id] => 18626658 [patent_doc_number] => 20230285458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 18/048489 [patent_app_country] => US [patent_app_date] => 2022-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36375 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048489 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/048489
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS Oct 20, 2022 Abandoned
Array ( [id] => 18466979 [patent_doc_number] => 20230201259 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 18/048796 [patent_app_country] => US [patent_app_date] => 2022-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36337 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048796 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/048796
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS Oct 20, 2022 Abandoned
Array ( [id] => 18536019 [patent_doc_number] => 20230241106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 18/047234 [patent_app_country] => US [patent_app_date] => 2022-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36746 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047234 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/047234
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS Oct 16, 2022 Abandoned
Array ( [id] => 18449537 [patent_doc_number] => 20230190813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 18/047195 [patent_app_country] => US [patent_app_date] => 2022-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36435 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047195 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/047195
PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS Oct 16, 2022 Abandoned
Array ( [id] => 18536020 [patent_doc_number] => 20230241107 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 18/047236 [patent_app_country] => US [patent_app_date] => 2022-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36382 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047236 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/047236
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS Oct 16, 2022 Abandoned
Array ( [id] => 18308802 [patent_doc_number] => 20230112702 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => NUCLEASE-MEDIATED MODULATION OF GENE EXPRESSION [patent_app_type] => utility [patent_app_number] => 17/961763 [patent_app_country] => US [patent_app_date] => 2022-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27091 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17961763 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/961763
NUCLEASE-MEDIATED MODULATION OF GENE EXPRESSION Oct 6, 2022 Abandoned
Array ( [id] => 18451513 [patent_doc_number] => 20230192791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 17/934663 [patent_app_country] => US [patent_app_date] => 2022-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39834 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17934663 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/934663
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS Sep 22, 2022 Abandoned
Array ( [id] => 18193024 [patent_doc_number] => 20230046543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 17/934673 [patent_app_country] => US [patent_app_date] => 2022-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17934673 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/934673
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS Sep 22, 2022 Abandoned
Array ( [id] => 18389952 [patent_doc_number] => 20230158170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => IL-1Ra GENE THERAPY FOR INTERVERTEBRAL DISC DEGENERATION [patent_app_type] => utility [patent_app_number] => 17/821761 [patent_app_country] => US [patent_app_date] => 2022-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25097 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821761 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/821761
IL-1Ra GENE THERAPY FOR INTERVERTEBRAL DISC DEGENERATION Aug 22, 2022 Pending
Array ( [id] => 18449367 [patent_doc_number] => 20230190643 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => IMPLANT FOR TREATMENT OF AN OCULAR CONDITION [patent_app_type] => utility [patent_app_number] => 17/868021 [patent_app_country] => US [patent_app_date] => 2022-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17868021 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/868021
IMPLANT FOR TREATMENT OF AN OCULAR CONDITION Jul 18, 2022 Abandoned
Array ( [id] => 18242827 [patent_doc_number] => 20230075138 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => METHODS FOR TREATING AND EVALUATING COVID-19 PATIENTS [patent_app_type] => utility [patent_app_number] => 17/863877 [patent_app_country] => US [patent_app_date] => 2022-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7924 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17863877 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/863877
METHODS FOR TREATING AND EVALUATING COVID-19 PATIENTS Jul 12, 2022 Pending
Array ( [id] => 18420480 [patent_doc_number] => 20230174942 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => NOVEL FABRICATION OF CORONARY BASED DECELLULARIZED HEART FLAPS TO TREAT ANEURYSM FOLLOWING MYOCARDIAL INFARCTION [patent_app_type] => utility [patent_app_number] => 17/862803 [patent_app_country] => US [patent_app_date] => 2022-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12812 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17862803 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/862803
NOVEL FABRICATION OF CORONARY BASED DECELLULARIZED HEART FLAPS TO TREAT ANEURYSM FOLLOWING MYOCARDIAL INFARCTION Jul 11, 2022 Abandoned
Array ( [id] => 18077424 [patent_doc_number] => 20220403036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => P-SELECTIN INHIBITOR, COMPOSITIONS THEREOF AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/842580 [patent_app_country] => US [patent_app_date] => 2022-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8450 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842580 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/842580
P-SELECTIN INHIBITOR, COMPOSITIONS THEREOF AND METHODS OF USE THEREOF Jun 15, 2022 Abandoned
Array ( [id] => 18036080 [patent_doc_number] => 20220380295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => METHOD FOR SEPARATING AND PREPARING MULTIPLE ISOMER COMPOUNDS FROM SEABUCKTHORN POMACE [patent_app_type] => utility [patent_app_number] => 17/743281 [patent_app_country] => US [patent_app_date] => 2022-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 178 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17743281 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/743281
METHOD FOR SEPARATING AND PREPARING MULTIPLE ISOMER COMPOUNDS FROM SEABUCKTHORN POMACE May 11, 2022 Abandoned
Array ( [id] => 19002042 [patent_doc_number] => 20240066113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => MESSENGER RNA VACCINES AGAINST WIDE SPECTRUM OF CORONAVIRUS VARIANTS [patent_app_type] => utility [patent_app_number] => 18/029758 [patent_app_country] => US [patent_app_date] => 2022-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16205 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18029758 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/029758
MESSENGER RNA VACCINES AGAINST WIDE SPECTRUM OF CORONAVIRUS VARIANTS Apr 11, 2022 Pending
Array ( [id] => 17911421 [patent_doc_number] => 20220313816 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => COMPOSITIONS AND METHODS FOR ANTIBODY-AS-ADJUVANT VACCINES AND THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 17/657696 [patent_app_country] => US [patent_app_date] => 2022-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6775 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17657696 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/657696
COMPOSITIONS AND METHODS FOR ANTIBODY-AS-ADJUVANT VACCINES AND THERAPEUTICS Mar 31, 2022 Abandoned
Array ( [id] => 17850470 [patent_doc_number] => 20220280511 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => CDK4/6 INHIBITORS FOR THE TREATMENT OF PSORIASIS [patent_app_type] => utility [patent_app_number] => 17/707741 [patent_app_country] => US [patent_app_date] => 2022-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11738 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17707741 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/707741
CDK4/6 INHIBITORS FOR THE TREATMENT OF PSORIASIS Mar 28, 2022 Pending
Menu